Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2017

14.09.2017 | Original Article

Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics

verfasst von: Newaz Hossain, Bharat Puchakayala, Pushpjeet Kanwar, Siddharth Verma, George Abraham, Zhanna Ivanov, Muhammad Obaid Niaz, Smruti R. Mohanty

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Several studies show inconsistencies in the rate of hepatitis C virus (HCV) detection among baby boomers (born 1945–1965). We conducted a cross-sectional HCV screening followed by a case-controlled comparison of the newly screened population with established HCV subjects.

Method

Enrollment was offered to subjects aged 40–75 at our gastroenterology and hepatology clinics. Demographic data and potential risk factors were obtained, and HCV antibody test was offered to those who had never been screened and compared with a group with established HCV. Logistic regression analysis and Fisher’s exact test were performed.

Results

Six hundred and seventy-five patients were offered participation, of whom 128 declined while 50 consented to participate but did not perform the HCV antibody test. Of 497 enrolled subjects, 252 patients had HCV, while 245 subjects (188 patients among “baby boomer”) underwent screening for HCV. There were more females (62.4 vs. 41.7%) and immigrants (34.7 vs. 22.2%) among the newly screened group. Among the screened population, five patients had HCV antibody (2.04%), and two of them had positive viral load (0.82%) of whom only one fell in the baby boomer category (0.53%). Compared to HCV group, screened group had significantly lower-risk factors, such as IV drug use (1.22 vs. 43.3%), intranasal cocaine use (14.3 vs. 49.6%), and blood transfusion (18.8 vs. 32.5%).

Conclusion

We found a slightly lower but similar prevalence of HCV antibody when screening based on birth cohort as compared to larger baby boomer studies. Future studies evaluating addition of other screening strategies or possibly universal screening may be needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562.CrossRefPubMed Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562.CrossRefPubMed
2.
Zurück zum Zitat Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.CrossRefPubMed Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.CrossRefPubMed
3.
Zurück zum Zitat Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521. (521.e511-516).CrossRefPubMed Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521. (521.e511-516).CrossRefPubMed
4.
Zurück zum Zitat Moyer VA. Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159:349–357.CrossRefPubMed Moyer VA. Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159:349–357.CrossRefPubMed
5.
Zurück zum Zitat Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263–270.CrossRefPubMed Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263–270.CrossRefPubMed
6.
Zurück zum Zitat Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1–39. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1–39.
7.
Zurück zum Zitat NIH Consensus Statement on Management of Hepatitis C: 2002 NIH consensus and state-of-the-science statements. 2002;19:1–46. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH consensus and state-of-the-science statements. 2002;19:1–46.
8.
Zurück zum Zitat Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, Md.). 2009;49:1335–1374.CrossRef Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, Md.). 2009;49:1335–1374.CrossRef
9.
Zurück zum Zitat Colvin HM, A. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. In: Colvin HM, Mitchell AE, eds. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C, 2010. Washington DC: National Academies Press. Colvin HM, A. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. In: Colvin HM, Mitchell AE, eds. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C, 2010. Washington DC: National Academies Press.
10.
Zurück zum Zitat Pyenson B, Fitch K, Iwasaki K. 2009. Consequences of hepatitis C virus (HCV): costs of a baby boomer epidemic of liver disease. New York: Milliman Inc. Pyenson B, Fitch K, Iwasaki K. 2009. Consequences of hepatitis C virus (HCV): costs of a baby boomer epidemic of liver disease. New York: Milliman Inc.
11.
Zurück zum Zitat Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (Baltimore, Md.). 2009;50:1750–1755.CrossRef Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (Baltimore, Md.). 2009;50:1750–1755.CrossRef
12.
Zurück zum Zitat Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61:1–32.PubMed Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61:1–32.PubMed
13.
Zurück zum Zitat Galbraith JW, Franco RA, Donnelly JP, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology (Baltimore, Md.). 2015;61:776–782.CrossRef Galbraith JW, Franco RA, Donnelly JP, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology (Baltimore, Md.). 2015;61:776–782.CrossRef
14.
15.
Zurück zum Zitat Litwin AH, Smith BD, Drainoni ML, et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis. 2012;44:497–503.CrossRefPubMed Litwin AH, Smith BD, Drainoni ML, et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis. 2012;44:497–503.CrossRefPubMed
16.
Zurück zum Zitat Myers RP, Crotty P, Town S, et al. Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. CMAJ Open. 2015;3:E62–E67.CrossRefPubMedPubMedCentral Myers RP, Crotty P, Town S, et al. Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. CMAJ Open. 2015;3:E62–E67.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol. 2013;108:981–989.CrossRefPubMed Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol. 2013;108:981–989.CrossRefPubMed
18.
Zurück zum Zitat Lyons MS, Kunnathur VA, Rouster SD, et al. Prevalence of diagnosed and undiagnosed hepatitis C in a midwestern urban emergency department. Clin Infect Dis. 2016;62:1066–1071.CrossRefPubMedPubMedCentral Lyons MS, Kunnathur VA, Rouster SD, et al. Prevalence of diagnosed and undiagnosed hepatitis C in a midwestern urban emergency department. Clin Infect Dis. 2016;62:1066–1071.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat O’Brien SF, Fan W, Xi G, et al. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion. 2008;48:902–909.CrossRefPubMed O’Brien SF, Fan W, Xi G, et al. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion. 2008;48:902–909.CrossRefPubMed
20.
Zurück zum Zitat Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat. 2011;18:474–481.CrossRefPubMed Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat. 2011;18:474–481.CrossRefPubMed
21.
Zurück zum Zitat Balasekaran R, Bulterys M, Jamal MM, et al. A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. Am J Gastroenterol. 1999;94:1341–1346.CrossRefPubMed Balasekaran R, Bulterys M, Jamal MM, et al. A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. Am J Gastroenterol. 1999;94:1341–1346.CrossRefPubMed
22.
Zurück zum Zitat Coppola N, Onorato L, Pisaturo M, et al. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015;21:11931–11940.CrossRefPubMedPubMedCentral Coppola N, Onorato L, Pisaturo M, et al. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015;21:11931–11940.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Ernst E, Sherman KJ. Is acupuncture a risk factor for hepatitis? Systematic review of epidemiological studies. J Gastroenterol Hepatol. 2003;18:1231–1236.CrossRefPubMed Ernst E, Sherman KJ. Is acupuncture a risk factor for hepatitis? Systematic review of epidemiological studies. J Gastroenterol Hepatol. 2003;18:1231–1236.CrossRefPubMed
24.
Zurück zum Zitat Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010;14:e928–e940.CrossRefPubMed Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010;14:e928–e940.CrossRefPubMed
25.
Zurück zum Zitat Mahboobi N, Porter SR, Karayiannis P, Alavian SM. Dental treatment as a risk factor for hepatitis B and C viral infection. A review of the recent literature. J Gastrointest Liver Dis. 2013;22:79–86. Mahboobi N, Porter SR, Karayiannis P, Alavian SM. Dental treatment as a risk factor for hepatitis B and C viral infection. A review of the recent literature. J Gastrointest Liver Dis. 2013;22:79–86.
26.
Zurück zum Zitat Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol. 2012;8:305–312. Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol. 2012;8:305–312.
27.
Zurück zum Zitat Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015;7:2323–2330.CrossRefPubMedPubMedCentral Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015;7:2323–2330.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology (Baltimore, Md.). 2011;53:737–745.CrossRef Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology (Baltimore, Md.). 2011;53:737–745.CrossRef
29.
Zurück zum Zitat Butterfield MI, Bosworth HB, Meador KG, et al. Gender differences in hepatitis C infection and risks among persons with severe mental illness. Psychiatr Serv. 2003;54:848–853.CrossRefPubMed Butterfield MI, Bosworth HB, Meador KG, et al. Gender differences in hepatitis C infection and risks among persons with severe mental illness. Psychiatr Serv. 2003;54:848–853.CrossRefPubMed
30.
Zurück zum Zitat Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis. 2014;59:755–764.CrossRefPubMedPubMedCentral Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis. 2014;59:755–764.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Smith BD, Yartel AK, Krauskopf K, et al. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. Clin Infect Dis. 2015;60:1145–1152.CrossRefPubMed Smith BD, Yartel AK, Krauskopf K, et al. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. Clin Infect Dis. 2015;60:1145–1152.CrossRefPubMed
32.
Zurück zum Zitat Turner BJ, Taylor BS, Hanson J, et al. High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers. Hepatology (Baltimore, Md.). 2015;62:1388–1395.CrossRef Turner BJ, Taylor BS, Hanson J, et al. High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers. Hepatology (Baltimore, Md.). 2015;62:1388–1395.CrossRef
33.
Zurück zum Zitat CDC. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002–2009. MMWR. 2011;60:537–541. CDC. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002–2009. MMWR. 2011;60:537–541.
34.
Zurück zum Zitat Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57:S32–S38.CrossRefPubMedPubMedCentral Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57:S32–S38.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59:1411–1419.CrossRefPubMed Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59:1411–1419.CrossRefPubMed
36.
Zurück zum Zitat Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR. 2015;64:453–458.PubMed Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR. 2015;64:453–458.PubMed
37.
Zurück zum Zitat Young KL, Huang W, Horsburgh CR, Linas BP, Assoumou SA. Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. J Viral Hepat. 2016;23:274–281.CrossRefPubMed Young KL, Huang W, Horsburgh CR, Linas BP, Assoumou SA. Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. J Viral Hepat. 2016;23:274–281.CrossRefPubMed
38.
Zurück zum Zitat Hsieh YH, Rothman RE, Laeyendecker OB, et al. Evaluation of the centers for disease control and prevention recommendations for hepatitis C virus testing in an urban emergency department. Clin Infect Dis. 2016;62:1059–1065.CrossRefPubMedPubMedCentral Hsieh YH, Rothman RE, Laeyendecker OB, et al. Evaluation of the centers for disease control and prevention recommendations for hepatitis C virus testing in an urban emergency department. Clin Infect Dis. 2016;62:1059–1065.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Shiffman ML. Universal screening for chronic hepatitis C virus. Liver Int. 2016;36(Suppl 1):62–66.CrossRefPubMed Shiffman ML. Universal screening for chronic hepatitis C virus. Liver Int. 2016;36(Suppl 1):62–66.CrossRefPubMed
40.
Zurück zum Zitat Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014;11:1.CrossRefPubMedPubMedCentral Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014;11:1.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Dieterich D. Current issues involving screening for hepatitis C virus infection. Gastroenterol Hepatol. 2015;11:778–780. Dieterich D. Current issues involving screening for hepatitis C virus infection. Gastroenterol Hepatol. 2015;11:778–780.
Metadaten
Titel
Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics
verfasst von
Newaz Hossain
Bharat Puchakayala
Pushpjeet Kanwar
Siddharth Verma
George Abraham
Zhanna Ivanov
Muhammad Obaid Niaz
Smruti R. Mohanty
Publikationsdatum
14.09.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2017
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4754-0

Weitere Artikel der Ausgabe 11/2017

Digestive Diseases and Sciences 11/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.